Lakefront Biotherapeutics NV GLPGF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.45M | 16.96M | 910.49M | -120.02M | -120.02M |
| Total Depreciation and Amortization | 3.54M | -- | 42.85M | 41.44M | 41.44M |
| Total Amortization of Deferred Charges | -- | -- | 4.41M | -- | -- |
| Total Other Non-Cash Items | -37.74M | -123.05M | -12.71M | 22.08M | 22.08M |
| Change in Net Operating Assets | -7.90M | 9.28M | -1.00B | -66.96M | -66.96M |
| Cash from Operations | -39.65M | -96.82M | -55.25M | -123.46M | -123.46M |
| Capital Expenditure | -33.70K | -143.90K | -1.87M | -4.72M | -4.72M |
| Sale of Property, Plant, and Equipment | 1.26M | 1.54M | 449.30K | -- | -- |
| Cash Acquisitions | -853.14M | -- | -- | -- | -- |
| Divestitures | 2.06M | 2.74M | 1.89M | -25.19M | -25.19M |
| Other Investing Activities | 967.82M | 67.81M | 84.07M | 114.69M | 114.69M |
| Cash from Investing | 117.96M | 71.95M | 84.54M | 84.79M | 84.79M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.07M | -510.00K | -405.00K | -600.00K | -600.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2.87M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4.58M | -596.70K | -471.50K | -681.00K | -681.00K |
| Foreign Exchange rate Adjustments | 6.70M | 819.00K | -1.57M | -1.96M | -1.96M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.42M | -24.64M | 27.25M | -41.31M | -41.31M |